208 related articles for article (PubMed ID: 25670908)
1. Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors.
Nakahara T; Moroi Y; Takayama K; Itoh E; Kido-Nakahara M; Nakanishi Y; Furue M
Onco Targets Ther; 2015; 8():259-63. PubMed ID: 25670908
[TBL] [Abstract][Full Text] [Related]
2. Analysis of sebum lipid composition and the development of acneiform rash before and after administration of egfr inhibitor.
Nakahara T; Moroi Y; Takayama K; Nakanishi Y; Furue M
Curr Oncol; 2015 Apr; 22(2):e124-7. PubMed ID: 25908917
[TBL] [Abstract][Full Text] [Related]
3. Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512).
Nishino K; Fujiwara Y; Ohe Y; Saito R; Miyauchi E; Kobayashi T; Nakai Y; Takahashi T; Shibata T; Hamaguchi T; Kikuchi K; Yamazaki N; Fukuda H; Nozawa K; Kiyohara Y
Support Care Cancer; 2021 May; 29(5):2327-2334. PubMed ID: 32918131
[TBL] [Abstract][Full Text] [Related]
4. Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study.
Takahashi H; Saito Y; Sugawara K; Sato M; Tairabune T; Ujiie H; Asaka J; Kudo K
Cancer Chemother Pharmacol; 2024 Apr; 93(4):319-328. PubMed ID: 38017207
[TBL] [Abstract][Full Text] [Related]
5. Reducing Acneiform Rash Induced by EGFR Inhibitors With Honeysuckle Therapy: A Prospective, Randomized, Controlled Study.
Liu Z; Tian T; Wang B; Lu D; Ruan J; Shan J
Front Pharmacol; 2022; 13():835166. PubMed ID: 35250582
[No Abstract] [Full Text] [Related]
6. Acneiform rash during lung cancer therapy with erlotinib (Tarceva(®)).
Owczarczyk-Saczonek A; Witmanowski H; Placek W
Postepy Dermatol Alergol; 2013 Jun; 30(3):195-8. PubMed ID: 24278074
[TBL] [Abstract][Full Text] [Related]
7. Skin rash during erlotinib for advanced non-small cell lung cancer: is age a clinical predictor?
Giuliani J; Marzola M
Arch Dermatol Res; 2013 Sep; 305(7):653-8. PubMed ID: 23536039
[TBL] [Abstract][Full Text] [Related]
8. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
[TBL] [Abstract][Full Text] [Related]
9. Perifollicular Xanthoma Occurring in Patients after Erlotinib Treatment.
Kim EH; Kim DM; Lee JY
Dermatol Ther (Heidelb); 2022 May; 12(5):1281-1286. PubMed ID: 35508798
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
11. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
Kikuchi K; Nozawa K; Yamazaki N; Nakai Y; Higashiyama A; Asano M; Fujiwara Y; Kanda S; Ohe Y; Takashima A; Boku N; Inoue A; Takahashi M; Mori T; Taguchi O; Inoue Y; Mizutani H
J Dermatol; 2019 Jan; 46(1):18-25. PubMed ID: 30402978
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
[TBL] [Abstract][Full Text] [Related]
15. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Tammaro KA; Baldwin PD; Lundberg AS
J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
[TBL] [Abstract][Full Text] [Related]
16. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zaborowska-Szmit M; Kowalski DM; Piórek A; Krzakowski M; Szmit S
Pharmacol Rep; 2016 Dec; 68(6):1140-1148. PubMed ID: 27588390
[TBL] [Abstract][Full Text] [Related]
17. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
Kudo K; Hotta K; Bessho A; Nogami N; Kozuki T; Kuyama S; Inoue K; Harita S; Okada T; Gemba K; Fujii M; Takigawa N; Oda N; Tanimoto M; Kiura K
Cancer Chemother Pharmacol; 2016 May; 77(5):1005-9. PubMed ID: 27029623
[TBL] [Abstract][Full Text] [Related]
18. Differential Toxicities of Tyrosine Kinase Inhibitors in the Management of Metastatic Lung Cancer.
Udupa KS; Rajendranath R; Sagar T; Thomas J
Indian J Med Paediatr Oncol; 2017; 38(1):15-17. PubMed ID: 28469331
[TBL] [Abstract][Full Text] [Related]
19. CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.
Jarząbek T; Rucińska M; Rogowski W; Lewandowska M; Tujakowski J; Habib M; Kowalczyk A; Byszek A; Dziadziuszko R; Nawrocki S
Mol Diagn Ther; 2015 Apr; 19(2):79-89. PubMed ID: 25721848
[TBL] [Abstract][Full Text] [Related]
20. Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment.
Tan AR; Steinberg SM; Parr AL; Nguyen D; Yang SX
Ann Oncol; 2008 Jan; 19(1):185-90. PubMed ID: 17878175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
